SCR430 / SupremeCure Pharma, RaND Biosciences - LARVOL DELTA

A Phase 1/2 Study of SC-43 in Combination With Cisplatin (clinicaltrials.gov) - P1/2; N=100; Not yet recruiting; Sponsor: RaND Biosciences

Clinical • Combination therapy • New P1/2 trial • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Accelerator Production of Scandium Radioisotopes: Sc-43, Sc-44, and Sc- 47. (PubMed, Curr Radiopharm) - "Significant technological advances have increased the quantity and quality of available radioscandium in the past decade, motivated in part by the chemical similarity of scandium to therapeutic radionuclides like Lu-177. The production and radiochemical isolation techniques applied to scandium radioisotopes are reviewed, focusing on charged particle and electron linac initiated reactions and using calcium and titanium starting materials."

Journal

Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors (clinicaltrials.gov) - P1; N=0; Withdrawn; Sponsor: SupremeCure Pharma Inc.; N=45 ➔ 0; Trial completion date: Nov 2021 ➔ Jun 2023; Not yet recruiting ➔ Withdrawn; Trial primary completion date: May 2021 ➔ Dec 2022

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Oncology • Solid Tumor

Sequence of Trypanosoma cruzi reference strain SC43 nuclear genome and kinetoplast maxicircle confirms a strong genetic structure among closely related parasite discrete typing units. (PubMed, Genome) - "TcVI genomes included several expansions not present in TcV strains. Comparative analysis of both nuclear and kinetoplast sequences clearly separated TcV from TcVI strains, which strongly supports the current DTU classification."

Journal